1995-1999
Doctor of Medicine, University of Washington School of Medicine Graduated with Honors
1989-1993
Bachelor of Arts, Cornell University, College of Arts and Sciences
Major: Psychology, Graduated with Distinction in All Subjects
Spring 1992
Semester abroad, Universidad de Sevilla, Seville, Spain
2005
Fellow, Vulvar Dermatology, Women’s Dermatologic Society
2004-2005
Senior Research Fellow (Funded by NIH Training Grant)
Conducted research in genotype-phenotype correlation in neurofibromatosis-1, under the guidance of Virginia Sybert, M.D. and Karen Stephens, PhD.
2002-2005
Resident Physician, Dermatology, University of Washington, Seattle WA
2000-2001
Dermatology Research Fellow, University of Washington, Seattle WA
Conducted independent research studying non-healing diabetic ulcers in a diabetic mouse model. Defined experimental design, coordinated personnel needed to conduct the study, and analyzed data.
1999-2000
Internship, Obstetrics and Gynecology, University of Washington, Seattle
2013-2017
Dermatologist, Private Practice, Dermatology Associates, Seattle, WA
2006-2013
Staff Physician and Managing Partner, Dermatology, Polyclinic, Seattle, WA
2009-Present
Assistant Clinical Professor, Dermatology, University of Washington
2005-2009
Clinical Instructor, University of Washington, Seattle, WA
2014-2016
Delegate, Washington State Medical Association
2013-Present
Trustee, King County Medical Society Board of Trustees
2002-2004
Resident Member, House Staff Association, University of Washington
Elected by peers to represent the house staff in decisions impacting compensation, working conditions, and social functions.
June 2004
Volunteer Medical Staff, Camp Discovery, Minnesota
Provided medical care and companionship for 40 teenagers with serious, disabling skin disease during an American Academy of Dermatology-sponsored summer camp.
2002-2004
Resident Member, House Staff Association, University of Washington
Elected by peers to represent the house staff in decisions impacting compensation, working conditions, and social functions.
American Board of Dermatology, 2005; Recertified in 2015.
King County Medical Society
Washington State Medical Association
American Academy of Dermatology
American Medical Association
Seattle Dermatologic Society
Women’s Dermatologic Society
Study 200583: A Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream Administered Once Daily for the Treatment of Plaque Psoriasis (GlaxoSmithKline)
Study 200704: A Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream Administered Once Daily for the Treatment of Atopic Dermatitis (GlaxoSmithKline)
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects with Facial Acne Vulgaris (Cassiopea)
A Double-Blind, Placebo-Controlled, Randomized Study on the Safety and Efficacy of Apremilast in Patients with Moderate to Severe Plaque Psoriasis Involving Palms and/or Soles (Innovaderm)
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Controlled, Two-Center, Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of TC cream in Treating Patients with Psoriasis Vulgaris (PRIG)
A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Pimecrolimus Cream, 1% and Reference Listed Elidel® (Pimecrolimus Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis (Symbio)
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate to Severe Plaque Psoriasis (Eli Lilly)
An Open-Label Study Assessing Long-Term Safety of DRM04 in Subjects with Primary Axillary Hyperhidrosis (Dermira)
A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of DRM04 in Subjects with Axillary Hyperhidrosis (Dermira)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients with Atopic Dermatitis (Regeneron)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of PF04965843 in Patients with Moderate to Severe Psoriasis (Pfizer)
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis (Regeneron)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis with Randomized Withdrawal and Retreatment VOYAGE 2 (Janssen)
A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults with Moderate to Severe Atopic Dermatitis Treated with Dupilumab (Regeneron)
XP-H-093, A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects with Moderate-to-Severe Chronic Plaque-Type Psoriasis (Xenoport)
A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Chronic Plaque Psoriasis (CHS-0214-04) (RaPsOdy) (Coherus)
A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with moderate to severe plaque prosiasis (Novartis)
A Phase 2, Randomized, Double-Blind, Vehicle Controlled, Comparator Study Of The Effect Of DRM04B and DRM04 In Subjects With Axillary Hyperhidrosis (Dermira)
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis who Achieve Complete Clearance on Biologics (Amgen)
An Open-Label Study of Dupilumab in Patients with Atopic Dermatitis who Participated in Previous Dupilumab Clinical Trials (Regeneron)
A Safety and Efficacy Study to Compare Dapsone Dermal Gel with Vehicle Control in Patients with Acne Vulgaris (Allergan)
A Phase 2, Randomized, Double-Blind, Vehicle Controlled, Dose-Ranging Study of the Effect of DRM04B in Subject With Axillary Hyperhidrosis (Dermira)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668_ Administered to Adult Patient with Moderate-to-Severe Atopic Dermatitis (Regeneron)
A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa (AbbVie)
A Phase 3 Open-Label Study of the Safety and Efficacy of Adalimumab in Subject with Moderate to Severe Hidradenitis Suppurativa (AbbVie)
Pharmacokinetic Evaluations of Ixekizumab following Subcutaneous Administration Using Prefilled Syringe or Auto Injector in Patient with Moderate-to-Severe Plaque Psoriasis (Lilly)
A Randomized, Vehicle-Controlled, Double-Blind, Parallel Group, Multi-Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects with Plaque Psoriasis (Maruho)
A Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study of the Efficacy and Safety of Apremilast (CC-10004), Etanercept, and Placebo, in Subjects with Moderate to Severe Plaque Psoriasis (Celgene)
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2 (Amgen)
A Multicenter Study with a Randomized, Double-Blind, Placebo=Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients with Moderate-to-Severe Plaque Psoriasis (Lilly)
